60 Avenue Rockefeller
Lyon 69008
France
33 4 78 74 44 38
https://www.erytech.com
Sector(s):
Industry:
Full-time employees: 149
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Gil Beyen BVBA | CEO & Director | 536.31k | N/A | 1962 |
Mr. Eric Soyer Ph.D. | Deputy GM, CFO & COO | 365.41k | N/A | 1966 |
Dr. Jérôme Bailly Pharm.D. | Deputy GM of Operations, Chief Quality Officer & Qualified Person | 224.92k | N/A | 1979 |
Naomi Eichenbaum | Director Investor Relations | N/A | N/A | N/A |
Mr. Brian Schwab | Chief Legal Officer & Gen. Counsel | N/A | N/A | 1965 |
Ms. Anne-Cécile Fumey | HR Director | N/A | N/A | 1975 |
Dr. Iman El-Hariry M.D., Ph.D. | Chief Medical Officer | N/A | N/A | 1960 |
Dr. Philip L. Lorenzi | Consultant & Member of Scientific Board | N/A | N/A | N/A |
Prof. Eric Raymond M.D., Ph.D. | Consultant & Member of Scientific Board | N/A | N/A | N/A |
Dr. Bridget Bax | Consultant & Member of Scientific Board | N/A | N/A | N/A |
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.
ERYTECH Pharma S.A.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.